Piper Tinka Markham, Rudenstine Sasha, Stancliff Sharon, Sherman Susan, Nandi Vijay, Clear Allan, Galea Sandro
Center for Urban Epidemiologic Studies, New York Academy of Medicine, New York, NY 10029, USA.
Harm Reduct J. 2007 Jan 25;4:3. doi: 10.1186/1477-7517-4-3.
Fatal heroin overdose is a significant cause of mortality for injection drug users (IDUs). Many of these deaths are preventable because opiate overdoses can be quickly and safely reversed through the injection of Naloxone [brand name Narcan], a prescription drug used to revive persons who have overdosed on heroin or other opioids. Currently, in several cities in the United States, drug users are being trained in naloxone administration and given naloxone for immediate and successful reversals of opiate overdoses. There has been very little formal description of the challenges faced in the development and implementation of large-scale IDU naloxone administration training and distribution programs and the lessons learned during this process.
During a one year period, over 1,000 participants were trained in SKOOP (Skills and Knowledge on Opiate Prevention) and received a prescription for naloxone by a medical doctor on site at a syringe exchange program (SEP) in New York City. Participants in SKOOP were over the age of 18, current participants of SEPs, and current or former drug users. We present details about program design and lessons learned during the development and implementation of SKOOP. Lessons learned described in the manuscript are collectively articulated by the evaluators and implementers of the project.
There were six primary challenges and lessons learned in developing, implementing, and evaluating SKOOP. These include a) political climate surrounding naloxone distribution; b) extant prescription drug laws; c) initial low levels of recruitment into the program; d) development of participant appropriate training methodology; e) challenges in the design of a suitable formal evaluation; and f) evolution of program response to naloxone.
Other naloxone distribution programs may anticipate similar challenges to SKOOP and we identify mechanisms to address them. Strategies include being flexible in program planning and implementation, developing evaluation instruments for feasibility and simplicity, and responding to and incorporating feedback from participants.
致命的海洛因过量使用是注射吸毒者(IDU)死亡的一个重要原因。这些死亡中有许多是可以预防的,因为通过注射纳洛酮(品牌名:纳曲酮)可以迅速且安全地逆转阿片类药物过量,纳洛酮是一种用于救治海洛因或其他阿片类药物过量使用者的处方药。目前,在美国的几个城市,吸毒者正在接受纳洛酮给药培训,并被给予纳洛酮以立即成功逆转阿片类药物过量。在大规模IDU纳洛酮给药培训和分发项目的开发与实施过程中所面临的挑战以及在此过程中吸取的经验教训,几乎没有正式的描述。
在一年时间里,超过1000名参与者在纽约市一个针头交换项目(SEP)现场接受了SKOOP(阿片类药物预防技能与知识)培训,并由医生开具了纳洛酮处方。SKOOP的参与者年龄在18岁以上,是SEP的现有参与者,以及当前或以前的吸毒者。我们介绍了SKOOP开发与实施过程中的项目设计细节和经验教训。本文所述的经验教训是由该项目的评估人员和实施人员共同阐述的。
在开发、实施和评估SKOOP过程中出现了六个主要挑战和经验教训。这些包括:a)围绕纳洛酮分发的政治气候;b)现行处方药法律;c)项目最初的低招募水平;d)制定适合参与者的培训方法;e)设计合适的正式评估的挑战;f)项目对纳洛酮反应的演变。
其他纳洛酮分发项目可能会遇到与SKOOP类似的挑战,我们确定了应对这些挑战的机制。策略包括在项目规划和实施中保持灵活性,开发可行性和简单性兼具的评估工具,以及回应并纳入参与者的反馈。